Prospects of medium specific activity 177Lu in targeted therapy of prostate cancer using 177Lu-labeled PSMA inhibitor

Targeted radionuclide therapy using 177Lu‐labeled peptidomimetic inhibitor of prostate specific membrane antigen (PSMA) viz. PSMA‐617 is emerging as one the most effective strategies for management of metastatic prostate cancer, which is one of the leading causes of cancer related death. The aim of...

Full description

Bibliographic Details

Published in:	Journal of labelled compounds & radiopharmaceuticals Vol. 59; no. 9; pp. 364 - 371
Main Authors:	Chakraborty, Sudipta, Chakravarty, Rubel, Shetty, Priyalata, Vimalnath, K. V., Sen, Ishita B., Dash, Ashutosh
Format:	Journal Article
Language:	English French German
Published:	Bognor Regis Blackwell Publishing Ltd 01-07-2016 Wiley Subscription Services, Inc
Subjects:	177Lu prostate cancer PSMA-617 specific activity targeted radionuclide therapy therapeutic dose
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!